Active Grants
2017
Integrative Network Modeling of Cognitive Resilience to AD National Institutes of Health National Institute on Aging R01 Dr. Kauwe, Subcontract PI
2016
Epidemiology of Alzheimer’s disease resilience and risk pedigrees National Institute of Health National Institute on Aging 1 RF1 AG054052-01 Dr. Kauwe, Principal Investigator
The broad, long-term goal of our research is to identify measurable risk and resilience factors for Alzheimer's disease, which will lead to better strategies for treatment and prevention of this devastating disease. In this proposal we will test hypotheses that genetic factors influence pedigrees that exhibit a statistical excess or deficit of Alzheimer's disease mortality. We will use the novel combination of two ongoing studies, the Utah Population Database and the Cache County Study on Memory in Aging, along with novel approaches to data analysis, to identify these factors. All data associated with our work will be harmonized with key efforts in the field and deposited into appropriate public databases.
2016
Pleiotropy GWAS of Alzheimer’s disease (A. Naj PI) National Institutes of Health National Institute on Aging R01 AG054060-02 Dr. Kauwe, Co-Investigator
The broad, long-term goal of our research is to solve the complex genetic architecture of Alzheimer's Disease, which will lead to better strategies for treatment and prevention of this devastating disease. In this proposal we will test hypotheses that genetic factors influence important clinical observations, such as the observation of Pleiotropic effects of APOE e4 on cerebrospinal fluid Aβ and tau levels, non-demented individuals with Alzheimer's disease pathology and variation in the rate of progression in clinically diagnosed Alzheimer's disease cases. We will use genome-wide marker data to detect loci that simultaneously affect cerebrospinal fluid amyloid beta and tau levels (pleiotropy), the relationships between Alzheimer's disease biomarkers (cerebrospinal fluid amyloid beta and tau) and Alzheimer's disease (referred to as rQTL), and gene-by-gene interactions. Identified loci are likely to affect both risk and/or progression of AD and will shed light on pathways connecting cerebrospinal fluid amyloid beta, tau, and Alzheimer's Disease.
2015
Research Supplements to Promote Diversity in Health-Related Research National Institutes of Health National Institute on Aging R01 AG042611-03S1 Dr. Kauwe, Principal Investigator
The broad, long-term goal of our research is to solve the complex genetic architecture of Alzheimer's Disease, which will lead to better strategies for treatment and prevention of this devastating disease. In this proposal we will test hypotheses that genetic factors influence important clinical observations, such as the observation of Pleiotropic effects of APOE e4 on cerebrospinal fluid Aβ and tau levels, non-demented individuals with Alzheimer's disease pathology and variation in the rate of progression in clinically diagnosed Alzheimer's disease cases. We will use genome-wide marker data to detect loci that simultaneously affect cerebrospinal fluid amyloid beta and tau levels (pleiotropy), the relationships between Alzheimer's disease biomarkers (cerebrospinal fluid amyloid beta and tau) and Alzheimer's disease (referred to as rQTL), and gene-by-gene interactions. Identified loci are likely to affect both risk and/or progression of AD and will shed light on pathways connecting cerebrospinal fluid amyloid beta, tau, and Alzheimer's Disease.
2015
Research Supplements to Promote Diversity in Health-Related Research National Institutes of Health National Institute on Aging R01 AG042611-03S2 Dr. Kauwe, Principal Investigator
The broad, long-term goal of our research is to solve the complex genetic architecture of Alzheimer's Disease, which will lead to better strategies for treatment and prevention of this devastating disease. In this proposal we will test hypotheses that genetic factors influence important clinical observations, such as the observation of Pleiotropic effects of APOE e4 on cerebrospinal fluid Aβ and tau levels, non-demented individuals with Alzheimer's disease pathology and variation in the rate of progression in clinically diagnosed Alzheimer's disease cases. We will use genome-wide marker data to detect loci that simultaneously affect cerebrospinal fluid amyloid beta and tau levels (pleiotropy), the relationships between Alzheimer's disease biomarkers (cerebrospinal fluid amyloid beta and tau) and Alzheimer's disease (referred to as rQTL), and gene-by-gene interactions. Identified loci are likely to affect both risk and/or progression of AD and will shed light on pathways connecting cerebrospinal fluid amyloid beta, tau, and Alzheimer's Disease.
2012
Pleiotropic and Interaction Effects on Alzheimer’s disease Risk and Progression National Institutes of Health National Institute on Aging R01 AG042611 Dr. Kauwe, Principal Investigator
The broad, long-term goal of our research is to solve the complex genetic architecture of Alzheimer's Disease, which will lead to better strategies for treatment and prevention of this devastating disease. In this proposal we will test hypotheses that genetic factors influence important clinical observations, such as the observation of Pleiotropic effects of APOE e4 on cerebrospinal fluid Aand tau levels, non-demented individuals with Alzheimer's disease pathology and variation in the rate of progression in clinically diagnosed Alzheimer's disease cases. We will use genome-wide marker data to detect loci that simultaneously affect cerebrospinal fluid amyloid beta and tau levels (pleiotropy), the relationships between Alzheimer's disease biomarkers (cerebrospinal fluid amyloid beta and tau) and Alzheimer's disease (referred to as rQTL), and gene-by-gene interactions. Identified loci are likely to affect both risk and/or progression of AD and will shed light on pathways connecting cerebrospinal fluid amyloid beta, tau, and Alzheimer's Disease.